Access to medicines and treatment: latest news

Access to medicines and treatment resources

Access to medicines and treatment features

Access to medicines and treatment news from aidsmap

More news

Access to medicines and treatment news selected from other sources

  • American HIV Activists Prepare for What Lies Ahead in 2018

    In the past year, health advocacy in the U.S. was a real stressor. President Donald Trump (along with the GOP-led houses of Congress) came into office fully focused on dismantling the Affordable Care Act (ACA) and reforming taxes to benefit the wealthy. This move could have taken us back to the days of AIDS Drug Assistance Program (ADAP) waiting lists, people with HIV being denied coverage, and people being refused coverage for pre-exposure prophylaxis (PrEP).

    16 January 2018 | The Body
  • India to launch national program to control viral hepatitis and aims to negotiate lower drug prices

    The health ministry is set to roll out a National Program for the Control of Viral Hepatitis from the 2018-19 financial year. An antiviral treatment that costs anywhere between $63,000 and $94,000 for the full course in the USA and Europe is to be provided free of cost at all government health organizations.

    09 January 2018 | Pharma Letter
  • I Couldn't Get PrEP, and Now I'm Living With HIV

    I'll never forget the day I discovered that I had HIV. It was a Monday, last October. I'd recently moved to San Francisco but was in Los Angeles for work when I got the call. The voice of the case manager on the other end sounded shaky, like he felt sorry for having to tell me something so important over the phone. My head swirled. How could this happen?

    28 November 2017 | The Body
  • Medicines Excitement in the Netherlands – New Health Minister announces firm action on “absurd” medicines pricing

    The new Minister of Health of the Netherlands, Bruno Bruins, came in guns blazing when he put the pharmaceutical industry on notice and announced on 22 November to “change the rules of the game” to tackle, what he called “absurd” medicines pricing.

    27 November 2017 | Medicines Law & Policy
  • UNAIDS announces nearly 21 million people living with HIV now on treatment

    In the year 2000, just 685 000 people living with HIV had access to antiretroviral therapy. By June 2017, around 20.9 million people had access to the life-saving medicines. Such a dramatic scale-up could not have happened without the courage and determination of people living with HIV demanding and claiming their rights, backed up by steady, strong leadership and financial commitment.

    20 November 2017 | UNAIDS press release
  • HIV in West and Central Africa – the state of an epidemic left behind

    The UNAIDS, Médecins Sans Frontières (MSF) and African Union 18-month catch-up plan aims to increase treatment access and reduce mortality in West and Central Africa.

    10 November 2017 | Avert
  • Why do some HIV drugs cost so much in the US? Pharma, insurers, advocacy groups and consumers weigh in

    As open enrollment begins November 1, millions of Americans are comparing insurance plans available on the Affordable Care Act insurance marketplace. Prescription copayments and which medications a health plan covers are key considerations for people living with HIV and for those taking regular prescription medications. The cost to the consumer is very different, however, from the price that insurers negotiate with pharmaceutical companies, and the debate around drug pricing has hit national headlines in recent years with cases like EpiPen and Daraprim. Drug pricing is a complicated issue, with pharmaceutical companies on one side, patient activists on the other, and consumers oftentimes stuck somewhere in the middle.

    03 November 2017 | BETA blog
  • Uganda: ARVs Stock-Out Sparks Fear of Mass Drug Resistance

    Civil society organisations and people living with HIV/Aids have warned that almost a million Ugandans could develop resistance to first-line anti-retroviral therapy if nothing is done about the nation-wide stock-out of drugs.

    01 November 2017 | AllAfrica
  • MSF Secures Deals For Key Hepatitis C Medicines, Price A Fraction Of Branded Drug

    Médecins Sans Frontières (MSF, Doctors Without Borders) announced today that it has secured deals for two key generic hepatitis C medicines, sofosbuvir and daclatasvir, for as low as US$1.40 per day, or US$120 per 12-week treatment course.

    31 October 2017 | Intellectual Property Watch
  • Close to 3 million people access hepatitis C cure

    On the eve of the World Hepatitis Summit in Brazil, WHO reports increasing global momentum in the response to viral hepatitis. A record 3 million people were able to obtain treatment for hepatitis C over the past two years, and 2.8 million more people embarked on lifelong treatment for hepatitis B in 2016.

    31 October 2017 | World Health Organization
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.